The appropriate utilization of animals within non-clinical research is always on the minds of drug developers. Lovelace Biomedical is always working with its team of experts to stay in touch with the current regulatory landscape and evaluating novel approaches to reduce the number of animals required in drug development. With the recent changes in the FDA Modernization Act Lovelace’s approach continues to evolve and some details can be found in their recent article with AAPS News Magazine: Bringing Clarity and Perspective to the FDA Modernization Act 2.0.
